We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels
New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels
Health

New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels

Last updated: July 8, 2025 1:05 am
Editorial Board Published July 8, 2025
Share
SHARE

Credit score: Pixabay/CC0 Public Area

A workforce of researchers on the Sant Pau Analysis Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, obtained by way of a easy blood take a look at, can predict the medical development of Alzheimer’s illness even in its earliest levels, when signs aren’t but evident. The examine, printed within the journal Neurology, reinforces the function of blood assessments in the way forward for diagnosing and monitoring dementias.

The examine, performed throughout the framework of the SPIN cohort (Sant Pau Initiative on Neurodegeneration), included 731 people with and with out cognitive impairment who had been adopted for a median of as much as 10 years.

The researchers analyzed ranges of p-tau217—a particular type of the tau protein related to neurodegeneration—and noticed that this marker not solely correlates with the presence of Alzheimer’s illness but additionally allows prediction of the speed of cognitive decline and development to extra superior levels of the illness, together with dementia.

“This marker has enormous potential as a clinical tool. It not only accurately identifies Alzheimer’s disease, but also allows us to estimate how fast it will progress—an essential factor in making therapeutic decisions,” says Dr. Ignacio Illán, researcher within the Neurobiology of Dementia group and neurologist at Sant Pau Hospital, who led the examine.

For her half, Judit Selma-González, first creator and analysis neuropsychologist, additionally from the Neurobiology of Dementia group, highlights that “one of the most relevant findings is that p-tau217 allows us to identify people who do not yet have cognitive symptoms but are at higher risk of developing the disease in the short or medium term. This can help us better select patients eligible to participate in clinical trials of disease-modifying treatments.”

An accessible different

Till now, essentially the most dependable biomarkers for detecting and monitoring Alzheimer’s illness have required invasive methods corresponding to lumbar puncture (to research cerebrospinal fluid) or expensive procedures corresponding to positron emission tomography (PET). Using plasma p-tau217 gives a noninvasive, extra accessible, and inexpensive different with each medical and analysis purposes.

The examine confirmed that p-tau217 ranges elevated progressively from the preclinical levels to the superior levels of dementia, and had been independently related to a better danger of cognitive decline (measured, amongst different instruments, with the Mini-Psychological State Examination) and conversion to dementia. In actual fact, the marker confirmed higher prognostic skill than its cerebrospinal fluid equal, p-tau181, which is extensively used as we speak.

Medical purposes and a promising future

This advance is especially related within the present context, the place disease-modifying therapies—corresponding to anti-amyloid antibodies—are already being authorized, and their use depends upon the stage of Alzheimer’s illness development. The opportunity of utilizing a blood take a look at to find out this medical stage and monitor its development represents a serious step towards extra customized and exact drugs.

“In a memory clinic, having access to this information through a blood test opens up possibilities that were previously limited to highly specialized centers,” notes Dr. Illán.

Extra info:
Judit Selma-Gonzalez et al, Affiliation of Plasma Phosphorylated Tau 217 With Medical Deterioration Throughout Alzheimer Illness Levels, Neurology (2025). DOI: 10.1212/WNL.0000000000213769

Offered by
Sant Pau Analysis Institute

Quotation:
New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/information/2025-07-blood-biomarker-alzheimer-disease-earliest.html

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

You Might Also Like

Psilocybin may reverse results of mind accidents ensuing from intimate associate violence, rat research finds

Predicting illness outbreaks utilizing social media

Deep mind stimulation succeeds for 1 in 2 sufferers with treatment-resistant extreme melancholy and nervousness in trial

Australian drug driving deaths have surpassed drunk driving. Here is the way to deal with it

Tooth of infants of confused moms come out earlier, suggests examine

TAGGED:AlzheimersBiomarkerBlooddiseaseearliestpredictsprogressionstages
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
How Can I Stay Me in a Workplace Full of Suits?
Fashion

How Can I Stay Me in a Workplace Full of Suits?

Editorial Board December 3, 2021
Vitamin A transporter reactivates latent HIV, offering one other step in direction of a remedy
Court docket: NJ federal prosecutor Alina Habba serving ‘unlawfully’
Frequent gene variant can defend in opposition to inherited type of dementia
West Nile virus discovered within the UK for the primary time: What you might want to know

You Might Also Like

New malaria drug heralds resistance breakthrough
Health

New malaria drug heralds resistance breakthrough

November 18, 2025
Chasing a successful streak: A brand new approach to set off responses within the physique by simulating psychological strain
Health

Chasing a successful streak: A brand new approach to set off responses within the physique by simulating psychological strain

November 18, 2025
The worldwide system for assessing organ dysfunction in critically sick sufferers is up to date after thirty years
Health

The worldwide system for assessing organ dysfunction in critically sick sufferers is up to date after thirty years

November 18, 2025
Breast most cancers remedies can enhance each survival probabilities and revenue
Health

Breast most cancers remedies can enhance each survival probabilities and revenue

November 18, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • Art
  • World

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?